SI1745078T1 - Postopek za äśiĺ äśenje albumin konjugatov - Google Patents

Postopek za äśiĺ äśenje albumin konjugatov

Info

Publication number
SI1745078T1
SI1745078T1 SI200530766T SI200530766T SI1745078T1 SI 1745078 T1 SI1745078 T1 SI 1745078T1 SI 200530766 T SI200530766 T SI 200530766T SI 200530766 T SI200530766 T SI 200530766T SI 1745078 T1 SI1745078 T1 SI 1745078T1
Authority
SI
Slovenia
Prior art keywords
albumin
albumin conjugates
conjugates
purification
solution
Prior art date
Application number
SI200530766T
Other languages
English (en)
Inventor
Nathalie Bousquet-Gagnon
Omar Quraishi
Dominique P Bridon
Original Assignee
Conjuchem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35196920&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1745078(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conjuchem Biotechnologies Inc filed Critical Conjuchem Biotechnologies Inc
Publication of SI1745078T1 publication Critical patent/SI1745078T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/303—Extraction; Separation; Purification by precipitation by salting out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/166—Fluid composition conditioning, e.g. gradient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200530766T 2004-04-23 2005-04-22 Postopek za äśiĺ äśenje albumin konjugatov SI1745078T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56522804P 2004-04-23 2004-04-23
EP05735795A EP1745078B1 (en) 2004-04-23 2005-04-22 Method for the purification of albumin conjugates

Publications (1)

Publication Number Publication Date
SI1745078T1 true SI1745078T1 (sl) 2009-12-31

Family

ID=35196920

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200530766T SI1745078T1 (sl) 2004-04-23 2005-04-22 Postopek za äśiĺ äśenje albumin konjugatov
SI200531088T SI2100904T1 (sl) 2004-04-23 2005-04-22 Trdna faza za uporabo v postopku čiščenja albumin konjugatov

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200531088T SI2100904T1 (sl) 2004-04-23 2005-04-22 Trdna faza za uporabo v postopku čiščenja albumin konjugatov

Country Status (25)

Country Link
US (3) US7307148B2 (sl)
EP (3) EP2100904B1 (sl)
JP (1) JP2007535507A (sl)
CN (1) CN1956998B (sl)
AT (2) ATE433999T1 (sl)
AU (1) AU2005235634B2 (sl)
BR (1) BRPI0510117A (sl)
CA (1) CA2564031A1 (sl)
DE (2) DE602005022239D1 (sl)
DK (2) DK2100904T3 (sl)
EA (1) EA011168B1 (sl)
ES (2) ES2328591T3 (sl)
HK (2) HK1096102A1 (sl)
HR (1) HRP20060362A2 (sl)
IL (1) IL178369A0 (sl)
MA (1) MA28587B1 (sl)
MX (1) MXPA06012260A (sl)
NO (1) NO20065037L (sl)
PL (2) PL1745078T3 (sl)
PT (2) PT2100904E (sl)
RS (1) RS20060578A (sl)
SI (2) SI1745078T1 (sl)
TN (1) TNSN06340A1 (sl)
WO (1) WO2005103087A1 (sl)
ZA (1) ZA200608475B (sl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
ES2185595T5 (es) * 1999-05-17 2009-12-17 Conjuchem Biotechnologies Inc. Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas.
BR0010750A (pt) * 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
AU2002233089B2 (en) * 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
DK1479691T3 (da) * 2001-05-31 2007-03-12 John Erickson Langvarigt aktive fuionspeptidinhibitorer for HIV infektion
EP1747233A4 (en) * 2004-05-06 2007-04-25 COMPOUNDS FOR SPECIFIC VIRAL TARGET
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
EP1976876A4 (en) * 2005-12-22 2010-01-13 Conjuchem Biotechnologies Inc PROCESS FOR PRODUCING PREFORMED ALBUMIN CONJUGATES AND THERAPEUTIC AGENT
EP2114437A2 (en) * 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
JP2010527376A (ja) * 2007-05-16 2010-08-12 コンジュケム バイオテクノロジーズ インコーポレイテッド 抗ウイルスペプチドのシステイン酸誘導体
WO2008157824A2 (en) * 2007-06-21 2008-12-24 Conjuchem Biotechnologies Inc. Thrombopoietin peptide conjugates
WO2009075859A2 (en) * 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
EP2247298B1 (en) * 2007-12-31 2016-08-31 New York University Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
ES2563553T3 (es) 2008-04-01 2016-03-15 Novo Nordisk A/S Conjugados de insulina-albúmina
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
BR112012012945A2 (pt) 2009-11-25 2020-12-29 Arisgen Sa Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
CA2935456C (en) * 2014-01-10 2018-09-18 Synthon Biopharmaceuticals B.V. Method for purifying cys-linked antibody-drug conjugates
EP3099809A4 (en) * 2014-01-31 2017-10-25 Ixcela, Inc. Covalently bound metabolites as biomarkers
US9616109B2 (en) * 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
CN105111306A (zh) * 2015-08-28 2015-12-02 北京工业大学 美洲短吻鳄白蛋白的分离方法
EP3433259B1 (en) 2016-03-24 2021-06-30 The Administrators of The Tulane Educational Fund Conjugates of tacrolimus, their compositions, and their uses
BR112020006189A2 (pt) * 2017-09-28 2020-10-13 Hanmi Pharm. Co., Ltd. conjugado de peptídeo-2 tipo glucagon (glp-2), derivado de glp-2 que compreende uma sequência de aminoácidos e seu método se preparação, ácido nucleico isolado que codifica o derivado de glp-2, vetor de expressão recombinante que compreende o ácido nucleico, transformante que compreende o vetor de expressão recombinante, composição farmacêutica para prevenir ou tratar uma ou mais doenças selecionadas
CN108840922A (zh) * 2018-06-04 2018-11-20 河北常山生化药业股份有限公司 分离白蛋白非结合物、白蛋白结合物和小分子化合物的方法
CN108977423A (zh) * 2018-08-17 2018-12-11 集美大学 一种从猪肺中分离提纯血管紧张素转化酶的方法
US11041847B1 (en) 2019-01-25 2021-06-22 Ixcela, Inc. Detection and modification of gut microbial population
CN109721653B (zh) * 2019-03-05 2023-02-03 嘉兴学院 一种胰高血糖素样肽-1片段类似物及其应用
CN115397846A (zh) * 2020-03-06 2022-11-25 昆山新蕴达生物科技有限公司 疏水性修饰的白蛋白及其制备方法和用途
WO2021222759A1 (en) * 2020-04-30 2021-11-04 Board Of Regents, The University Of Texas System Albumin drug conjugates and use thereof for the treatment of cancer
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206199A (en) 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
US4251631A (en) 1978-02-23 1981-02-17 Research Products Rehovot Ltd. Cross-linked enzyme membrane
US4423034A (en) 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US4678671A (en) * 1981-12-15 1987-07-07 Cordis Europa N.V. Conjugates of anticoagulant and protein
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4745100A (en) 1985-05-14 1988-05-17 Eye Research Institute Of Retina Foundation Stimulation of tear secretion
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4859604A (en) 1987-08-27 1989-08-22 Ampor, Inc. Composition for stabilization of diagnostic reagents
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US5725804A (en) 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
JPH06509551A (ja) 1991-04-05 1994-10-27 ジェネンテク，インコーポレイテッド Ｇｐ　ＩＩ↓ｂＩＩＩ↓ａに対する高い特異性を有する血小板凝集阻害剤
US5103233A (en) 1991-04-16 1992-04-07 General Electric Co. Radar system with elevation-responsive PRF control, beam multiplex control, and pulse integration control responsive to azimuth angle
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
JPH07102148B2 (ja) * 1992-05-20 1995-11-08 株式会社ミドリ十字 遺伝子操作により得られるヒト血清アルブミンの製造方法、およびそれにより得られるヒト血清アルブミン含有組成物
US5807827A (en) 1992-06-12 1998-09-15 Des-Tyr Dynorphin Partnership Des-Tyr dynorphin analogues
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US20020018751A1 (en) 1993-10-15 2002-02-14 BRIDON Dominique P. Cellular and serum protein anchors for diagnostic imaging
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
DK145493D0 (da) 1993-12-23 1993-12-23 Dako As Antistof
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
WO1995027496A1 (en) 1994-04-07 1995-10-19 Proteinix Company Vasoactive intestinal polypeptide
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
CA2157219C (en) * 1994-08-31 2010-10-05 Munehiro Noda Process for purifying recombinant human serum albumin
US5939390A (en) 1995-03-09 1999-08-17 Novo Nordisk A/S Pharmaceutical composition
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US6277583B1 (en) 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
EP0915910B1 (de) 1996-06-05 2006-01-18 Roche Diagnostics GmbH Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ATE417622T1 (de) 1996-08-08 2009-01-15 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
US6956026B2 (en) 1997-01-07 2005-10-18 Amylin Pharmaceuticals, Inc. Use of exendins for the reduction of food intake
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
WO1998011437A1 (en) 1996-09-16 1998-03-19 Conjuchem, Inc. Affinity labeling libraries with tagged leaving groups
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP2001504105A (ja) 1996-11-12 2001-03-27 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１ペプチドの利用
DE69738074T2 (de) * 1996-11-15 2008-05-21 Genentech, Inc., South San Francisco Reinigung von neurotrophinen
US6723530B1 (en) 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US5981488A (en) 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
EP1007561B1 (en) 1997-11-07 2002-04-17 Conjuchem, Inc. Novel conjugates of opioids and endogenous carriers
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
WO1999024075A2 (en) 1997-11-07 1999-05-20 Conjuchem, Inc. Affinity markers for human serum albumin
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US6107489A (en) 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US20030170250A1 (en) 1998-03-23 2003-09-11 Ezrin Alan M. Local delivery of long lasting therapeutic agents
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US7399489B2 (en) * 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
ES2244416T5 (es) 1999-01-14 2020-01-03 Amylin Pharmaceuticals Llc Formulaciones novedosas de agonistas de la exendina y métodos de administración de los mismos
DE60044041D1 (de) 1999-01-14 2010-04-29 Amylin Pharmaceuticals Inc Exendine zur Glucagon Suppression
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
BR0010750A (pt) 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
ES2185595T5 (es) * 1999-05-17 2009-12-17 Conjuchem Biotechnologies Inc. Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas.
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
DE19926154A1 (de) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
ES2291210T3 (es) 1999-06-21 2008-03-01 Eli Lilly And Company Uso sinergistico de tiazolidindionas con peptido-1 tipo glucagona y sus agonistas para tratar la diabetes no insulina-dependiente.
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
DE19932782A1 (de) * 1999-07-14 2001-01-18 Biotest Pharma Gmbh Verfahren zur chromatographischen Fraktionierung von Plasma oder Serum, so erhaltene Präparate und deren Verwendung
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
WO2001066417A1 (en) * 2000-03-09 2001-09-13 Crisplant A/S A discharge and stacker device
ES2484966T3 (es) * 2000-04-12 2014-08-12 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
EP1282436B1 (en) 2000-05-19 2008-06-11 Amylin Pharmaceuticals, Inc. Treatment of acute coronary syndrome with glp-1
MXPA02006118A (es) 2000-10-20 2004-08-23 Amylin Pharmaceuticals Inc Tratamiento de la invernacion del miocardio y cardiopatia diabetica con un peptido glp-1.
US7259233B2 (en) 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
JP2004520395A (ja) * 2001-02-02 2004-07-08 コンジュケム，インコーポレーテッド 長期持続性成長ホルモン放出因子誘導体
AU2002233089B2 (en) 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
DK1479691T3 (da) 2001-05-31 2007-03-12 John Erickson Langvarigt aktive fuionspeptidinhibitorer for HIV infektion
SE526227C2 (sv) * 2002-05-15 2005-08-02 North China Pharmaceutical Group Metod för rening av rekombinant humant serumalbumin
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
KR20060109940A (ko) * 2003-12-18 2006-10-23 노보 노르디스크 에이/에스 알부민-유사제에 연결된 신규 ｇｌｐ-1 유사체

Also Published As

Publication number Publication date
ATE433999T1 (de) 2009-07-15
DK1745078T3 (da) 2009-10-26
AU2005235634B2 (en) 2011-10-20
US7307148B2 (en) 2007-12-11
EA011168B1 (ru) 2009-02-27
SI2100904T1 (sl) 2010-10-29
NO20065037L (no) 2007-01-11
AU2005235634A1 (en) 2005-11-03
ES2347902T3 (es) 2010-11-22
MA28587B1 (fr) 2007-05-02
EP2230257A1 (en) 2010-09-22
EP2100904B1 (en) 2010-07-07
PT2100904E (pt) 2010-09-24
CN1956998A (zh) 2007-05-02
PL2100904T3 (pl) 2011-05-31
DE602005014969D1 (de) 2009-07-30
DK2100904T3 (da) 2010-11-08
HRP20060362A2 (en) 2007-03-31
CN1956998B (zh) 2012-12-12
CA2564031A1 (en) 2005-11-03
BRPI0510117A (pt) 2007-09-25
US20120022234A1 (en) 2012-01-26
IL178369A0 (en) 2007-02-11
PL1745078T3 (pl) 2009-12-31
US20080146783A1 (en) 2008-06-19
EA200601959A1 (ru) 2007-04-27
RS20060578A (en) 2008-11-28
EP2100904A1 (en) 2009-09-16
TNSN06340A1 (en) 2008-02-22
MXPA06012260A (es) 2006-12-15
US20050267293A1 (en) 2005-12-01
ES2328591T3 (es) 2009-11-16
EP1745078B1 (en) 2009-06-17
ATE473244T1 (de) 2010-07-15
HK1136305A1 (en) 2010-06-25
JP2007535507A (ja) 2007-12-06
EP1745078A1 (en) 2007-01-24
DE602005022239D1 (de) 2010-08-19
HK1096102A1 (en) 2007-05-25
WO2005103087A1 (en) 2005-11-03
ZA200608475B (en) 2007-11-28
EP1745078A4 (en) 2007-08-01
PT1745078E (pt) 2009-09-17

Similar Documents

Publication Publication Date Title
IL178369A0 (en) Method for the purification of albumin conjugates
WO2007109163A3 (en) Wash buffer and method of using
TW200740839A (en) Methods of purifying Fc region containing proteins
EP1568710A3 (en) Antibody purification method
NO20014239L (no) Sett for radiomerking av proteiner med yttrium-90
FI1888636T4 (fi) Vasta-aineiden puhdistusmenetelmä
MX2009005012A (es) Una forma pura de rapamicina y procedimiento para la recuperacion y purificacion de la misma.
ATE476501T1 (de) Verfahren zur reinigung von factor vii
ATE461199T1 (de) Verfahren zur trennung und reinigung von hydrocodon durch präparative chromatographie
WO2007001834A3 (en) Methods and apparatus for improving the sensitivity of capillary zone electrophoresis
WO2002101021A3 (en) Purification of human serum albumin
HK1138290A1 (en) Method of purification of hydrophobic proteins
MX342922B (es) Purificacion de insulina.
DK1064066T3 (da) Adsorptionschromatografi
DE602004018674D1 (de) Grosstechnisches verfahren zur abtrennung und aufreinigung von fentanyl durch präparative umkehrphasenchromatographie
WO2009071767A3 (fr) Procédé d'elimination des mercaptans par adsorption sur un tamis moléculaire avec régénération réactive du tamis
SE0104412D0 (sv) Flash chromatographic method
FI894235A (fi) Foerfarande foer aotervinning av proteiner ur en loesning.
PL362013A1 (en) Method for fabrication of capillary chromatographic column